Cart
sales@molnova.com
Epertinib
CAS No. 908305-13-5
Epertinib ( S-222611;S222611 )
Catalog No. M16528 CAS No. 908305-13-5
Epertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 410 | Get Quote |
|
| 50MG | 1593 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEpertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEpertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively.
-
DescriptionEpertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively; does not inhibit KDR, IGF1R, SRC, KIT, PDGFRβ; phosphorylation of EGFR and HER2 kinases in NCI-N87 cells with IC50 of 4.5 and 1.6 nM, shows growth inhibition of NCI-N87 cell with IC50 of 8.3 nM; shows potent antitumor activity over lapatinib in a variety of xenograft models, exhibits excellent activity and could be effective against bone and brain metastasis.Breast Cancer Phase 2 Clinical
-
SynonymsS-222611;S222611
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number908305-13-5
-
Formula Weight560.03
-
Molecular FormulaC30H27ClFN5O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC#C/C(C1=CC2=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)N=CN=C2C=C1)=N\OC[C@@H]5NCCOC5
-
Chemical Name(R,Z)-1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)but-2-yn-1-one O-morpholin-3-ylmethyl oxime
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tanaka H, et al. Cancer Sci. 2014 Aug;105(8):1040-8.
2. Spicer J, et al. Eur J Cancer. 2015 Jan;51(2):137-45.
3. Tanaka Y, et al. Sci Rep. 2018 Jan 10;8(1):343.
2. Spicer J, et al. Eur J Cancer. 2015 Jan;51(2):137-45.
3. Tanaka Y, et al. Sci Rep. 2018 Jan 10;8(1):343.
molnova catalog
related products
-
AZD8931 diFuMaric ac...
AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.
-
CHMFL-EGFR-202
CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).
-
ICA-105574
ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
